Medkart Pharmacy plans public quality report as India’s NSQ drug alerts more than double

Medkart Pharmacy has placed its Medkart Assured quality-control programme at the centre of a broader transparency push as scrutiny of medicine quality intensifies across India. The Ahmedabad-based generic pharmacy chain plans to publish a Medkart Assured Quality and Transparency Report covering the number of batches tested, rejection rates, therapy categories and testing protocols. The move follows the identification of 1,879 Not of Standard Quality drug samples during 2025, more than double the 877 recorded in 2024. The announced Medkart Assured model combines pharmaceutical plant audits, procurement from Schedule M-compliant facilities and two rounds of testing at laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories. The strategic question is whether Medkart Pharmacy can turn quality assurance from an invisible procurement function into a credible retail differentiator without overstating what private testing can prove.

Why has the sharp rise in India’s NSQ medicine alerts created a commercial opening for Medkart Pharmacy?

The increase in Not of Standard Quality alerts is significant, but the headline number requires careful interpretation. An NSQ classification means that a tested batch failed one or more prescribed quality standards or specifications. It does not automatically mean that every medicine produced under the same brand, by the same manufacturer or within the same therapy category is defective, nor is an NSQ finding necessarily the same as identifying a counterfeit or deliberately falsified product.

The rise also reflects wider participation by state laboratories and a more visible surveillance system. State authorities accounted for 1,163 of the 1,879 NSQ samples reported in 2025, compared with 339 of the 877 samples recorded in 2024. Part of the increase therefore represents more testing, broader reporting and improved aggregation of state-level findings rather than conclusive evidence that medicine manufacturing quality deteriorated at the same rate.

That distinction matters because poorly framed discussion can unintentionally damage confidence in the entire generic medicine market. India’s healthcare system depends heavily on affordable medicines, and broad suspicion could cause patients to abandon lower-cost alternatives without any clinical or batch-specific justification. Medkart Pharmacy is attempting to occupy the middle ground between complacency and alarm by arguing that affordability should be accompanied by visible evidence of supplier scrutiny.

Commercially, this gives Medkart Pharmacy an opportunity to differentiate itself on trust rather than price alone. Generic pharmacy chains usually compete through savings, product availability, pharmacist guidance and store reach. A transparent quality-control layer could create an additional reason for patients to remain loyal, particularly when medicines are used continuously for diabetes, hypertension, cardiovascular disease and other chronic conditions where switching behaviour is influenced by confidence as much as cost.

How is Medkart Assured designed to move quality control beyond basic supplier certification?

The Medkart Assured model introduces additional retailer-controlled checks between pharmaceutical manufacturing and final dispensing. The programme includes independent audits of partner manufacturing facilities, procurement aligned with Schedule M requirements and compulsory dual testing through third-party laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories. Products that clear these checks receive the Medkart Assured designation in stores and through the company’s digital channels.

This approach is strategically important because a pharmacy retailer does not control the manufacturing line. Medkart Pharmacy must therefore exercise influence through supplier selection, procurement conditions, testing requirements and the threat of rejection. A retailer that can redirect purchasing volumes away from suppliers with repeated failures may create a commercial incentive for manufacturers to improve documentation, consistency and corrective action.

Dual testing could reduce the possibility that a purchasing decision rests on a single result, but its value will depend on the programme’s design. Testing the same samples twice is different from testing separate samples from different points within a batch. Likewise, confirming identity and assay does not necessarily evaluate every possible failure mode, including dissolution, sterility, impurities, packaging integrity and storage-related degradation.

The programme should therefore be judged by the depth of its testing protocols rather than the number of tests alone. A label can simplify communication for patients, but the underlying quality system must remain more sophisticated than the label. Otherwise, Medkart Pharmacy could create a perception of absolute assurance that no sampling-based programme can realistically provide.

What must the Medkart Quality and Transparency Report disclose to establish credibility?

The proposed transparency report is potentially the most consequential part of the announcement because it could convert internal quality processes into comparable public evidence. Publishing only the number of products tested would offer limited insight. The report will need a clear denominator showing how many batches were purchased, how many were tested, how samples were selected and whether testing covered every batch or only a risk-based subset.

Rejection rates must also be accompanied by reasons. A failure involving packaging documentation carries a different risk profile from a sterility failure, incorrect active ingredient content or inadequate dissolution. Combining these outcomes into one percentage could generate an impressive-looking statistic while giving patients, regulators and procurement professionals little information about the seriousness of the problems detected.

The report would be stronger if it identified therapy categories, dosage forms, test parameters, laboratory accreditation status and the period covered. It should explain how disputed results are investigated, whether confirmatory testing is performed and what happens to rejected inventory. Medkart Pharmacy should also disclose whether a rejection prevents only the affected batch from entering its network or triggers a broader review of the supplier.

Consistency will be as important as detail. A single transparency report could attract attention, but recurring publication using the same methodology would create a meaningful performance record. Independent review of the reporting framework could further reduce the risk that Medkart Pharmacy is perceived as marking its own homework, even if the underlying laboratory tests are conducted externally.

Why does revised Schedule M compliance not eliminate the need for retailer-level testing?

Schedule M establishes Good Manufacturing Practice requirements covering pharmaceutical facilities, production systems, equipment, documentation, quality management and related controls. Revised requirements were implemented for larger manufacturers from June 28, 2024, while eligible small and medium manufacturers received a conditional extension until December 31, 2025. The regulatory baseline has therefore become more demanding across India’s pharmaceutical manufacturing sector.

Compliance remains essential, but it is not a guarantee that every batch will meet every specification. Manufacturing involves raw materials, equipment calibration, environmental controls, operator performance, process validation, packaging and storage conditions. A facility can maintain an approved quality system while an individual batch still experiences a deviation or test failure.

Retailer-level testing can function as an additional checkpoint, particularly when products are sourced from multiple manufacturers. It can also help a pharmacy chain compare supplier performance over time and identify patterns that may not be visible from licences or certificates alone. This creates a more active procurement model in which supplier approval is treated as an ongoing process rather than a one-time documentation exercise.

However, private testing must complement rather than mimic regulatory enforcement. Medkart Pharmacy cannot replace government sampling, inspections, recalls or legal action. Its commercial advantage will come from detecting risks before products enter its own distribution network and publishing enough information to show that supplier controls have practical consequences.

Can public quality data improve consumer confidence in generic medicines without increasing unnecessary fear?

Generic medicine adoption depends on more than scientific equivalence and regulatory approval. Patients frequently judge quality through price, packaging, familiarity, physician recommendations and previous experience. When a lower-priced medicine looks different from a familiar branded product, the price saving can sometimes be misinterpreted as evidence of inferior manufacturing.

Medkart Pharmacy’s strategy could help separate affordability from poor quality by demonstrating that low-cost medicines can still be subjected to structured supplier assessment and laboratory testing. Pharmacists will play an important role because patients are unlikely to interpret assay results, dissolution specifications or manufacturing audits without explanation. The company’s in-store communication must therefore remain accurate, accessible and free from claims of zero risk.

There is also a danger that aggressive promotion of private testing could imply that medicines sold through other channels are inadequately checked. That message would be commercially tempting but analytically weak. A responsible campaign should explain that NSQ alerts concern identified batches and that quality assurance involves manufacturers, regulators, laboratories, wholesalers, pharmacies and storage operators.

The strongest consumer message is not that one retailer can guarantee perfection. It is that quality decisions should be evidence-based, batch-conscious and open to scrutiny. That position allows Medkart Pharmacy to promote generic medicines while recognising that confidence must be earned continuously.

What financial and operational risks could Medkart Pharmacy face from expanding its quality programme?

Additional testing creates direct costs through laboratory fees, sampling, logistics, staff, supplier audits and inventory management. The commercial case will depend on whether these expenses are offset by higher customer retention, increased prescription volumes, better supplier terms or expansion into markets where medicine quality is a major purchasing concern. If costs are passed directly to consumers, the programme could weaken the affordability proposition that supports generic pharmacy growth.

Testing can also delay product availability. Holding inventory until results are received may increase working-capital requirements and complicate replenishment, particularly for medicines with volatile demand or limited supplier options. Medkart Pharmacy will need service-level arrangements with laboratories and alternative sourcing plans to prevent quality controls from producing frequent stock shortages.

Supplier relationships could become more difficult when batches are rejected or results are disputed. Manufacturers may question sampling methods, laboratory procedures or storage conditions after dispatch. Medkart Pharmacy will require documented chain-of-custody procedures and a clear escalation process to ensure that commercial disagreements do not compromise patient protection.

Transparency introduces reputational risk as well. Publishing rejection data may initially generate uncomfortable headlines, especially if readers treat a high rejection rate as evidence that the retailer previously sourced poor-quality products. Yet withholding such information after promising disclosure could be more damaging. The long-term credibility of the programme will depend on Medkart Pharmacy’s willingness to publish unfavourable findings and explain corrective action without minimising them.

Could Medkart Pharmacy’s disclosure strategy become a wider standard for Indian pharmacy retailers?

If Medkart Pharmacy publishes detailed and recurring quality information, competitors may face pressure to explain their own procurement and testing controls. Large pharmacy chains, digital health platforms and hospital networks could respond with supplier scorecards, expanded batch testing or independent quality certifications. This would shift competition beyond discounts and delivery times towards evidence of product governance.

Manufacturers could also be affected. Suppliers with consistent results may gain preferred status and larger purchasing commitments, while companies with repeated failures could lose access to organised retail channels. Over time, retailer-generated quality data could influence negotiations, contract terms, insurance requirements and inventory decisions.

The broader opportunity is the development of a more transparent pharmaceutical supply chain in which quality information follows products through manufacturing, distribution and dispensing. Digital batch tracking, laboratory integration and faster recall communication could eventually make quality alerts more actionable for pharmacies and patients. Medkart Pharmacy’s programme is not yet that system, but public reporting could be a practical step towards it.

The immediate test is execution. The Medkart Assured Quality and Transparency Report must move beyond broad promises and show how many batches were assessed, which standards were applied, what failed and what action followed. If the disclosure is detailed, repeatable and independently credible, Medkart Pharmacy could strengthen its brand and raise expectations across Indian healthcare retail. If the report is selective or heavily promotional, the initiative risks becoming another badge in a sector already crowded with assurances.

What are the key takeaways from Medkart Pharmacy’s generic medicine quality transparency strategy?

• Medkart Pharmacy is attempting to compete through visible quality governance rather than relying only on lower generic medicine prices.
• The increase from 877 NSQ samples in 2024 to 1,879 in 2025 partly reflects expanded state-level reporting and should not be treated as proof of a market-wide quality collapse.
• NSQ findings apply to tested batches and are not automatically equivalent to counterfeit or spurious medicines.
• Independent plant audits and dual laboratory testing could give Medkart Pharmacy greater control over suppliers, but the value depends on sampling depth and test design.
• The proposed transparency report will require denominators, rejection reasons, test parameters and corrective actions to become commercially credible.
• Schedule M compliance provides a manufacturing baseline, while retailer-level testing can add a separate procurement checkpoint.
• Greater disclosure could strengthen patient confidence in generic medicines if communication avoids exaggerating either risks or assurances.
• Testing costs, inventory delays, supplier disputes and working-capital pressure could complicate programme expansion.
• Competitors may face pressure to disclose their own quality-control systems if Medkart Pharmacy publishes useful and recurring data.
• The first report will determine whether Medkart Assured becomes a measurable quality platform or remains primarily a marketing designation.